http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
-
PTC Therapeutics to Host Deep Dive Webinar on Splicing Platform
-
PTC Therapeutics (PTCT) to Monetize Portion of Risdiplam Royalty Stream for $650 Million
-
PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million
-
PTC Therapeutics (PTCT) Reports First Patient Dosed in Phase 1 Trial for PTC857
-
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
-
PTC Therapeutics (PTCT) Announces CHMP Recommendation of Translarna Label Update for Non-Ambulatory Patients with DMD
-
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
-
PTC Therapeutics (PTCT) Commences Phase 2/3 Clinical Trial to Evaluate PTC299 for Treatment of COVID-19
-
PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19
-
PTC Therapeutics (PTCT) Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with SMA
-
PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy
-
PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic
-
PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals
-
PTC Therapeutics to Host First Deep Dive Webinar on Bio-e Platform
-
PTC Therapeutics (PTCT) to Acquire Censa Pharmaceuticals
-
PTC Therapeutics to Acquire Censa Pharmaceuticals
-
Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy
-
PTC Therapeutics Announces New Leadership Appointments
-
PTC Therapeutics (PTCT) Announces FDA Has Extended PDUFA Date for Risdiplam NDA to August 24
-
PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)
-
PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy
-
PTC Therapeutics (PTCT) Announces First Publication of Real-World Data Showing Translarna Significantly Preserves Ability to Walk for Longer in Children with DMD
-
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
-
PTC Therapeutics Launches A No-Cost Testing Program to Drive AADC Deficiency Patient Identification
-
Intrexon Reports Third Quarter 2019 Financial Results
-
Risdiplam (RG7916) Pivotal SUNFISH Study Demonstrates Statistically Significant Improvement for Patients with Type 2/3 Spinal Muscular Atrophy
-
PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
-
PTC Therapeutics (PTCT) Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
-
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
-
PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing
-
PTC Therapeutics (PTCT) Reports Data from STRIDE Registry Demonstrating Translarna (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
-
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna™ (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
-
PTC Therapeutics (PTCT) Announces Risdiplam SMA Data Demonstrating Continued Benefit Presented at World Muscle Society Congress
-
Risdiplam Spinal Muscular Atrophy Data Demonstrating Continued Benefit Presented at World Muscle Society Congress
-
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winners
-
PTC Therapeutics Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
-
PTC Therapeutics Expands Presence in New Jersey by Securing State-of-the-Art Biologics Facility
-
PTC Therapeutics (PTCT) Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
-
PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics
-
PTC Therapeutics (PTCT) Announces CHMP Adopts Negative Opinion of Translarna Application for Label Expansion
-
PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion
-
Pre-Open Stock Movers 11/14: (CRBP) (HAR) (DGII) (MENT) Higher; (DVAX) (HEAR) (ACM) Lower (more...)
-
INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims Against PTC Therapeutics, Inc. and Strongly Encourages Investors to Contact the Firm
-
Pre-Open Stock Movers 02/23: (NEWP) (MMSI) (TXRH) Higher; (PTCT) (FIT) (WDC) Lower (more...)
-
Streetinsider.com's Hot Lunchtime Reads 10/16: (AAPL) (TWTR) (PTCT) (ZFGN)
-
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)

